The biotech firm targets Q1 2026 for a pivotal trial of its non-hormonal contraceptive while anticipating Flora Sync LF5 revenue in June.
Daré Bioscience outlined plans to advance its Ovaprene contraceptive into a Phase III trial in 2026, targeting 2,500 exposure cycles. The company aims to expand its clinical pipeline as part of a broader business strategy discussed during its Q1 2026 earnings call.
Management confirmed expectations for Flora Sync LF5 revenue to begin in June, signaling progress in its commercialization efforts. The update follows prior guidance on pipeline execution and financial performance, though specific consensus or prior-period comparisons were not disclosed.
No immediate market reaction was detailed in the source, focusing instead on strategic execution and pipeline development.